论文部分内容阅读
用高效液相色谱法测定:11名健康受试者分别服用茶碱国产控释片和进口控释胶囊后的药代动力学及相对的生物利用度.国产控释片的主要药代参数为:T_(1/2)Ke:14.07±1.32h,T_(1/2)Ka:1.26±0.14h,V/F(C):46.2±9.25 l,Cmax:4.21±0.53mg/l,F:0.844,血药浓度曲线显示峰型平钝,及其在24h内原形药从尿中的排出百分率为:9.7%.9名哮喘或慢性阻塞性肺病(COPD)患者服用国产控释片和进口控释胶囊的稳态药代动力学结果显示:国产控释片在有效血浓度内的波动度比进口控释胶囊小,(P< 0.05).我们认为:应用茶碱类药物时,应进行血药浓度监测,有利于指导临床正确用药.
The pharmacokinetics and relative bioavailability of 11 controlled-release tablets of theophylline and controlled-release capsules were determined by high performance liquid chromatography.The main pharmacokinetic parameters of the controlled release tablets (1/2) Ke: 14.07 ± 1.32h, T 1/2 (1/2) Ka: 1.26 ± 0.14h, V / F (C): 46.2 ± 9.25 l, Cmax: 4.21 ± 0.53mg / l, F: 0.844, the plasma concentration curve showed a flat blunt type, and its protoporphychia excretion rate in urine within 24h: 9.7% .9 patients with asthma or chronic obstructive pulmonary disease (COPD) taking domestic controlled release tablets and imported control The steady-state pharmacokinetic results of the capsule showed that the fluctuation of the controlled-release tablets in the effective blood concentration was less than that of the controlled-release capsules (P <0.05) .We think: when using theophylline drugs, Drug concentration monitoring, is conducive to guiding clinical correct medication.